Core Insights - Ocular Therapeutix's experimental eye drug, Axpaxli, has demonstrated superior efficacy in maintaining vision compared to Regeneron's Eylea in a late-stage trial, marking a significant advancement in treatment for wet age-related macular degeneration (AMD) [1] Company Summary - Ocular Therapeutix reported that Axpaxli outperformed Eylea, with 74% of patients maintaining vision at 36 weeks after a single 0.45 mg dose, compared to nearly 56% for Eylea's 2 mg dose [1] - After one year, approximately 66% of Axpaxli patients maintained their vision, while less than 50% of Eylea patients did [1] - The drug also showed better fluid control in the eye, indicating improved disease management, and many Axpaxli patients did not require additional "rescue" injections for almost a year, potentially reducing clinic visits [1] Industry Summary - Wet AMD affects around 1.7 million Americans, leading to vision loss due to abnormal blood vessel growth in the retina [1] - Ocular Therapeutix plans to discuss the trial data with the U.S. Food and Drug Administration and anticipates submitting a marketing application based on these results [1] - Following the announcement, Ocular's shares experienced a significant decline of about 30% in premarket trading, despite a previous gain of nearly 39% in 2025 [1]